Fluanxol Depot

Flupentixol decanoate

Schizophrenia & allied psychoses, especially w/ symptoms eg, hallucinations, paranoid delusions & thought disturbances along w/ apathy, anergy & withdrawal.

IM Adult Maintenance treatment: 20-40 mg (1-2 mL) every 2-4 wk depending on the response. Inj vol >2 mL should be distributed between 2 inj sites.

Hypersensitivity. Decreased level of consciousness regardless of cause (eg, intoxication w/ alcohol, barbiturates or opiates), circulatory collapse or coma.

Neuroleptic malignant syndrome have been reported w/ antipsychotic agents. Caution must be exercised when using Flupentixol in patients w/ organic brain syndrome, convulsions & advanced liver disease. Flupentixol in doses up to 25 mg daily is not recommended in excited or overactive patients. Insulin & glucose response may be altered, & patients w/ diabetes may require adjustment of their hypoglycaemic treatment. Flupentixol may cause QT prolongation. Persistently prolonged QT intervals may increase the risk of malignant arrhythmias. Flupentixol should therefore be used w/ caution in susceptible individuals (patients w/ hypokalaemia, hypomagnesaemia or a genetic predisposition to arrhythmia) & in patients w/ a history of CV disorders eg, QT prolongation, excessive bradycardia (<50 beats per min), a recent acute MI, untreated heart failure or cardiac arrhythmia. Concomitant treatment w/ other antipsychotics should be avoided. Cases of venous thromboembolism (VTE), leukopenia, neutropenia & agranulocytosis have been reported w/ antipsychotics, including zuclopenthixol decanoate. Long-acting depot antipsychotics should be used w/ caution in combination w/ other medicines known to have a myelosuppressive potential. Elderly patients: Flupentixol should be used w/ caution in patients w/ risk factors for stroke. Fluanxol Depot should not be used during pregnancy unless clearly necessary. Fluanxol Depot 20 mg/mL is unsuitable for patients who require a sedative effect. Caution must be exercised in elderly patients & patients w/ hepatic impairment. Not recommended in childn.

Somnolence, akathisia, hyperkinesia, hypokinesia; dry mouth. Increased appetite, increase wt; insomnia, depression, nervousness, agitation, decreased libido; tremor, dystonia, dizziness, headache; abnormalities of visual accommodation, visual disturbances; tachycardia, palpitation; dyspnoea; increased salivation, constipation, vomiting, dyspepsia, diarrhoea; excessive sweating, pruritus; myalgia; urinary disturbances, urinary retention; asthenia, fatigue.

Flupentixol may potentiate the sedative effect of alcohol & the effects of barbiturates & other CNS depressants, may increase or reduce the effect of antihypertensive agents & the antihypertensive effect of guanethidine & similar agents. Concomitant use of antipsychotics & lithium increases the risk of neurotoxicity. Flupentixol may reduce the effect of levodopa & adrenergic agents. Concomitant use of metoclopramide & piperazine increases the risk of extrapyramidal problems. Co-administration of medicinal products known to prolong the QT interval is not recommended. Agents known to cause electrolyte disturbances eg, thiazide diuretics (for hypokalemia) & agents known to increase the plasma levels of flupentixol should also be used w/ caution concurrently w/ flupentixol, as they may increase the risk of QT prolongation & malignant arrythmias.

Antipsychotics

N05AF01 - flupentixol ; Belongs to the class of thioxanthene derivatives antipsychotics.

P₁S₁S₃